Drug intelligence / Profile preview

VENBETA6890

Development stage: Phase 1
Lead developer: Pharmaron
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral

Overview

VENBETA6890 is an orally administered, human monoclonal IgA antibody developed by Pharmaron CPC for the prevention and treatment of diarrheal diseases. Its primary mechanism is presumed to be neutralization of enteric pathogens in the gastrointestinal tract. The drug is currently being evaluated in a phase 1 clinical trial for its safety, tolerability, and anti-diarrheal activity in healthy adults challenged with enterotoxigenic Escherichia coli (ETEC), a common cause of infectious diarrhea. The main therapeutic area under investigation is digestive system disorders, specifically dysentery and related diarrheal illnesses[1][2][3].

Other names: IgA VENBETA6890

Beyond the preview

Go deeper on VENBETA6890.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VENBETA6890.

Explore the full profile